Raise standards for preclinical cancer research
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index; 3 of the 9 sources its claims cite were checked for support.
Overview
CoChat Summary
TL;DR
This Nature Comment argues that many landmark preclinical oncology findings are not reproducible and calls for higher standards in methods, reporting, and incentives. It reports that Amgen confirmed only 6 of 53 landmark papers (11%) and cites Bayer’s finding that about 25% of published preclinical studies could be validated.
Key findings
- In Amgen’s ten-year retrospective analysis, scientific findings were confirmed in only 6 of 53 “landmark” preclinical cancer papers (11%); non-reproduced studies often lacked blinding, relied on single experiments such as one Western blot, or presented selected data.
- Bayer HealthCare reported that only about 25% of published preclinical studies could be validated to the point at which projects could continue; published cancer research represented 70% of the studies analysed in that report, with possible overlap with Amgen’s 53 papers.
- Citation data showed non-reproduced articles in journals with impact factor >20 had a mean of 248 citations (range 3–800) versus 231 (range 82–519) for reproduced articles; for impact factor 5–19, non-reproduced articles had a mean of 169 citations (range 6–1,909) versus 13 (range 3–24) for reproduced articles.
- The authors recommend reporting negative data, blinding preclinical experiments, validating reagents, repeating critical experiments, avoiding single cell lines or models, requiring patient-selection biomarkers, and changing academic incentives.
Methods
- This is a Nature Comment/perspective, not a primary experimental study; it synthesizes Amgen’s ten-year retrospective analysis of experiments performed prospectively and cites a Bayer HealthCare report.
- Amgen selected 53 “landmark” papers describing completely new approaches or alternative clinical uses, attempted confirmation, used additional models, contacted original authors, exchanged reagents, and repeated experiments under the authors’ direction, occasionally in the original investigator’s laboratory.
- The analysis reports counts of confirmed findings and citation metrics from Google Scholar, May 2011; the recommendations are proposed changes rather than tested interventions.
Limitations
- Stated: validation attempts may have failed because of technical differences or difficulties despite efforts to ensure otherwise; additional models were used; when findings could not be reproduced, authors were contacted and experiments were repeated under their direction.
- Stated: papers were deliberately selected as “landmark” and described something completely new, so some data might not hold up; Bayer’s analysed studies may overlap with Amgen’s 53 papers.
- Evident: as a Comment, the text provides no detailed systematic protocol, inclusion criteria, statistical methods, or full dataset; the citation analysis is descriptive and limited to two impact-factor strata.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
3 Valid · 1 Not valid · 6 Not checked · 12 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Sadly, clinical trials in oncology have the highest failure rate compared with other therapeutic areas.”
What the sources say
- Partly supportedcites [1] Hutchinson, L. & Kirk, R. Nature Rev. Clin. Oncol. 8, 189–190 (2011). sourceExperimental — accuracy not yet measured
The opening passage of our copy (labelled Abstract; page unavailable) says cancer-drug attrition is much higher than in other therapeutic areas, citing 5% of anticancer agents versus 20% of cardiovascular agents reaching licensure. That comparison covers development from preclinical activity through phase III, not failure rates specifically among clinical trials; it also does not explicitly establish a highest-rate ranking. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although we in the cancer field hoped that this would lead to more effective drugs, historically, our ability to translate cancer research to clinical success has been remarkably low 1 .”
What the sources say
- Supportedcites [1] Hutchinson, L. & Kirk, R. Nature Rev. Clin. Oncol. 8, 189–190 (2011). source
The opening passage (labeled Abstract in our copy; no page given) reports that only 5% of agents with preclinical anticancer activity are licensed after demonstrating sufficient efficacy in phase III testing. It also says cancer drug attrition is much higher than in other therapeutic areas, supporting the claim of historically low translation to clinical success. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In studies for which findings could be reproduced, authors had paid close attention to controls, reagents, investigator bias and describing the complete data set.”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For results that could not be reproduced, however, data were not routinely analysed by investigators blinded to the experimental versus control groups.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Investigators frequently presented the results of one experiment, such as a single Western-blot analysis.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
12 more claims
Create a free account to see all 22 claims and every source verdict.
- It may state two separate claims as one. 2
- Probably not a substantial claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“there are other more common sources of unreliability in the literature (41)(42)(43)(44)”
From Misconduct accounts for the majority of retracted scientific publications (2012) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“many established scientific results in the social (49, 50) and biomedical (51-53) sciences cannot readily be replicated.”
From Misinformation in and about science (2021) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A landmark study conducted by Glenn Begley and his team in 2012 concluded that most cancer research studies were not reproducible, by alarmingly reporting that 47 of 53 published findings could not be replicated [13].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In cell biology, two industrial laboratories reported success replicating the original results of landmark findings in only 11% and 25% of the attempted cases ( 10, 11 ).”
From Estimating the reproducibility of psychological science (2015) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Concerns about reproducibility are widespread across disciplines ( 921 ).”
From Estimating the reproducibility of psychological science (2015) · cites this paper as [10]
Experimental — accuracy not yet measured
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Believe it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888
Do Pressures to Publish Increase Scientists' Bias? An Empirical Support from US States Data
Fanelli, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010271 · Cited by 805
High drug attrition rates—where are we going wrong?
Hutchinson, L., & Kirk, R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.34 · Cited by 517
Drug development and clinical trials—the path to an approved cancer drug
Rubin, E. H., & Gilliland, D. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.22 · Cited by 135
Raising the bar for cancer therapy models
Francia, G., & Kerbel, R. S. (2010) · Nature Biotechnology · doi:10.1038/nbt0610-561 · Cited by 54
Cited by
Items 2,801–2,889 of 2,889
1+1 > 2: Integrating Analytical Techniques in the Age of AI
Limongi, R., Brei, V. A., Almeida, V. D. S. E., & Francisco, E. D. R. (2025) · BAR - Brazilian Administration Review · doi:10.1590/1807-7692bar2025250230 · Cited by 1
Be Biologist: Basic Knowledge for Biologist Which No One Told 5
Kim, J.-E. (2025) · Journal of Biotechnology and Bioindustry · doi:10.37503/jbb.2025.13.30
Predicting Adaptively Chosen Observables in Quantum Systems
Huang, J., Lewis, L., Huang, H.-Y., & Preskill, J. P. (2026) · PRX Quantum · doi:10.1103/xhn1-vnp9 · Cited by 5
Predicting target and chemical druggability
Oprea, T. I., & Avram, S. I. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00084-4 · Cited by 1
Zempleni, O., Towler, B., & Jones, C. (2026) · Octopus · doi:10.57874/60pj-8x73
Replication studies: a win-win for early-career training and behavioral ecology
Laskowski, K. L., O’Dea, R. E., & Pick, J. L. (2026) · Behavioral Ecology · doi:10.1093/beheco/araf158 · Cited by 2
van den Berg, H., Niekerk, S. E. V., Netshimbupfe, M. H., & van der Kooy, F. (2026) · Planta Medica · doi:10.1055/a-2816-1526 · Cited by 1
“…SvN; HM investigation, HvdB; FvdK methodology, HvdB; FvdK project administration, FvdK software, HvdB supervision, FvdK; SvN; HM validation, HvdB writing – original draft, HvdB writing review and editing, FvdK; SvN; HM All authors have read and agreed to the published version of the manuscript”
Balakumar, P., Nandakumar, K., & Jagadeesh, G. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109015 · Cited by 2
Slim, K., Chadli, D., & Occéan, B. (2026) · Journal de Chirurgie Viscérale · doi:10.1016/j.jchirv.2026.01.005
Nakadate, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062593
Social and behavioral experiments, history of
Olthof, M., Maatman, F. O., & Bisselink, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26629-4.00279-3
Lohse, S. (2026) · European Journal for Philosophy of Science · doi:10.1007/s13194-026-00727-y · Cited by 2
“In par - ticular two articles (Begley & Ellis, 2012 ; Prinz et al., 2011) have sparked debate and co-initiated talk about a “replication crisis” in biomedicine.”
Grand manuel de parapsychologie scientifique
Bancel, P. A., & Varvoglis, M. (2025) · Dunod eBooks · doi:10.3917/dunod.evrar.2025.01.0176
Diagnosing scientific replicability through probabilistic distinguishability
Wang, P., Cao, H., & Wen, X. (2026) · Bioinformatics · doi:10.1093/bioinformatics/btag140
Scientific workflow for state sequence analysis: a simple and reproducible tool
Mrenda, B. M., Pellegrin, L., Marchi, J., Chaudet, H., & Texier, G. (2026) · Discover Applied Sciences · doi:10.1007/s42452-026-08591-4
Mannstadt, M., & Wein, M. N. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13683-2.00041-4
Qui est l'assassin au cours du sepsis? : l'inflammation ou la prolifération bactérienne ?
de Tymowski, C. (2020) · theses.fr (ABES) · doi:10.70675/ed19121fza61fz403czb053z70b4c1f5a3a6
Griseti, E. (2020) · theses.fr (ABES) · doi:10.70675/57c1a8a7zadbaz40d3zb8baze25015dbc60e · Cited by 1
Réduire la stigmatisation de la maladie mentale : du contact imaginé au contact incarné
Schuhl, J. (2020) · theses.fr (ABES) · doi:10.70675/6518276ez4b1fz4a99za875za70c90e5f798
Gelsleichter, Y. A., Banzi, R., Naudet, F., Vinatier, C., Kertész, I., & Varga, M. (2026) · F1000Research · doi:10.12688/f1000research.172013.2
Essays in Economics of Science : Publication quality and research incentives
Bernard, O. (2020) · theses.fr (ABES) · doi:10.70675/91ea0ebfzda05z4467zbfb5zad935fc9c35d
Fine-scale modelling of the dynamics of phytoplankton communities
Picoche, C. (2022) · theses.fr (ABES) · doi:10.70675/fc1722e4z6066z40f0z8fdaz93eab2f9c461 · Cited by 1
La philosophie computationnelle : pour une reprise en main épistémique du monde numérique
Etienne, H. (2022) · theses.fr (ABES) · doi:10.70675/d2cbaf0dz1dcdz44daz9c9cz45bb5d3c64fd · Cited by 1
Deb, V. K., Mukherjee, A., Pathak, S., Paul, S., Duttaroy, A. K., & Adhikari, S. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1775442 · Cited by 1
Dalloul, I., Barden, M., Wilcke, J. C., Bernhard, S., Ellenbach, N., Boulesteix, A., Abken, H., & Kobold, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.10.717659
“Similarly, Bayer and Amgen, two major industrial laboratories, state that they could only replicate 11 % and 25 % of the results, respectively, from several major cancer studies (13, 14).”
Okada, N., Oshima, K., Maruko, A., Nishi, A., & Kobayashi, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083539
Agent-Driven Validation of Oncology Therapeutic TargetsPreprint
Huang, K.-L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.29.721634
“4 These findings, echoed by subsequent commentary and meta-research, 5 highlight that many “sexy” targets may be based on fragile or context-dependent data.”
A role for core facilities in improving research rigour
North, A. J., & Anderson, K. I. (2026) · Journal of Microscopy · doi:10.1111/jmi.70110
Hansford, J. R., Manoharan, N., Khan, S., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00461
Open science in STEMM disciplines – and lessons for open social science
Dunleavy, P., & Monteath, T. (2026) · LSE Press eBooks · doi:10.31389/lsepress.dos.c
From superficial scholarship to algorithmic slop in analytical chromatography
Salehi‐Reyhani, A. (2026) · Journal of Chromatography B · doi:10.1016/j.jchromb.2026.125130
Forty years of changes in scientific publishing: from conflict of interest to generative AI
Bauchner, H. (2026) · Health Affairs Scholar · doi:10.1093/haschl/qxag125
Backlund, A., Samaniego, C. H., Rangaraj, V. R., Campbell, C., Cocito, C., Souweidane, M. M., Dahmane, N., & Greenfield, J. P. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-5402
The Hypothesis Race Model for evaluation of research findingsPreprint
Kelly, R. E. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.28.728385
“Researchers from Amgen noted that only 6/53 of their studies confirmed previous findings, a low success rate described as “not sustainable” [58].”
Barile, V., Kuzikov, M., Cui, W., Ianevski, A., Iannelli, F., Roca, M. S., Reinshagen, J., Axelsson, H., Leone, A., Jensen, A. J., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119575 · Cited by 1
Zebrafish swimming towards cures: a scalable NAM platform for drug discovery
Cutinho, V., & Williams, C. H. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104716
Grimes, D. R. (2026) · Significance · doi:10.1093/jrssig/qmag048
Lee, C. J. (2026) · Social Epistemology · doi:10.1080/02691728.2026.2669578
“…on Reproducibility and Replicability in Science et al. 2019, 46) – have found low rates of replication success for studies in biomedicine (Begley and Ellis 2012; Ioannidis 2005; Prinz, Schlange, and Asadullah 2011), psychology (R. Klein et al. 2014; Open Science Collaboration 2015a), and…”
Progressing from Simple to Multidimensional Models Towards a Biopsychosocial Framework of Addiction
Regier, P. S. (2026) · Current Addiction Reports · doi:10.1007/s40429-026-00752-0 · Cited by 3
Class, B., Bourguet, D., & Guillemaud, T. (2026) · Insights the UKSG journal · doi:10.1629/uksg.744 · Cited by 2
The Brazilian Reproducibility Network
Carneiro, C. F. D., Centeno, E. G. Z., de Gois, T. S., Umpierre, D., Andrades, M. É., Veiga, V. S. D. O., Ceneviva, R., Andrejew, R., Santos, R., & Amaral, O. B. (2026) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765202620251108
Reimag(in)ing representative images
Barkley, R. J. R., Brodrick, A. J., & Parker, J. S. L. (2026) · doi:10.69761/ggmj4852
Die Kontextualität von Symptomen und die Entwicklung einer responsiven Neuropsychologie
Frisch, S. (2026) · cultura & psyché · doi:10.1007/s43638-026-00115-6
Vaiid, N., Yadav, S., Alansari, R. A., Lee, M. K., & Allareddy, V. (2026) · Seminars in Orthodontics · doi:10.1053/j.sodo.2026.06.010 · Cited by 1
Biotechnology’s Ethical and Reproducibility Crisis: Beyond the Hype
Gao, Q. (2026) · doi:10.17352/qbt.000001 · Cited by 1
Reproducibility as a missing scientific criterion in life cycle assessment: a reporting framework
Kamali, A. K., Koyamparambath, A., Laratte, B., & Sonnemann, G. (2026) · The International Journal of Life Cycle Assessment · doi:10.1007/s11367-026-02708-y · Cited by 1
Estimating the replicability of Brazilian biomedical sciencePreprint
Initiative, T. B. R. (2026) · eLife · doi:10.7554/elife.111001
Estimating the replicability of Brazilian biomedical sciencePreprint
Initiative, T. B. R. (2026) · eLife · doi:10.7554/elife.111001.1 · Cited by 1
Hu, L., Cao, H., Zhang, Y., & Ma, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1881594
Kumar, S., & Shaikh, M. M. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70607
“Current methodological guidance suggests that the primacy of a mechanism should ideally be confirmed by in vivo gain-and loss- of-function approaches before assigning it [3].”
Dükel, M., Emen, F. M., Kalabalik, Z. A., et al. (2026) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-026-03532-9
Kistermann, L., Strunk, M., Knorr, I. J., Talbot, S. R., Ernst, L., & Tolba, R. H. (2026) · Animals · doi:10.3390/ani16142226
Distal Myopathies and Beyond: An Updated Overview of the Welander Distal Myopathy
García-Rubio, A., Santos, J. S. D. L., & Izquierdo, J. M. (2026) · Cells · doi:10.3390/cells15141302
“More broadly, concerns regarding the reproducibility and translational validity of preclinical models have been widely discussed in biomedical research, underscoring the importance of standardized and biologically appropriate experimental systems [125,126].”
AI-driven Approaches for Target Discovery in Drug Design
Iwata, H. (2026) · Royal Society of Chemistry eBooks · doi:10.1039/9781837070206-00039
Stop comparing spells: a defense of mechanistic reasoning in quantitative medicine
Mangalam, M., & Kiyono, K. (2026) · Frontiers in Digital Health · doi:10.3389/fdgth.2026.1878419
“Ioannidis [15] and Begley and Ellis [39] documented widespread irreproducibility driven partly by analytical flexibility that remains invisible when methods are treated as standardized procedures rather than chains of reasoning requiring justification.”
Abdurrahman, Y. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7191639
Badal, S. (2026) · Springer eBooks · doi:10.1007/978-3-032-28873-8_8
Liu, M., & Ye, S. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05764-1
Borodacheva, J. V., Shamsiev, I. D., & Shalaginova, I. G. (2026) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-026-02049-1
“Issues of reproducibility of results in behavioral neuroscience [Crabbe et al., 1999; Mandillo et al., 2008; Wahlsten, 2003] and in biomedical research in general [Begley et al., 2012] have been widely discussed over the past decade.”
Douglas, Y. K., & Adham, S. A. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08763-1
“A critical challenge moving forward is integrating spheroid data into broader translational modeling frameworks while improving cross-study reproducibility [45, 46].”
Zhang, L., Gupta, A., Wang, Y., Sharma, R., Lawal, B., Hou, G., & Wang, X. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.17.745283
Biospecimen Science: The Foundation for Reliable and Reproducible Research
Betsou, F., Kelly, C. M., Somiari, S., et al. (2026) · Biopreservation and Biobanking · doi:10.1177/19475535261481642
Jeffers, M. S., Tangamornsuksan, W., Dorus, B., Bedford, P., Kimmelman, J., McIsaac, D. I., Fergusson, D. A., & Lalu, M. M. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106456
Gaburro, S., Berridge, B. R., Kelley, N. W., von Keutz, E., Ferrer, M., Roper, C. S., Fossler, M. J., Bajramovic, J. J., Valentin, J., McGovern, T., et al. (2026) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2026.106237
Xie, Y., Zhang, D., & Tang, P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177908
Parrot, M., Xu, N., Adnan, M., Cave, J., Ghandehari, H., Nance, E. A., & Yellepeddi, V. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70176
Fox, J. W., & Ambulos, N. P. (2026) · Journal of Biomolecular Techniques JBT · doi:10.7171/001c.167753
Yang, J., Xin, G., & Li, D. (2026) · Chemosensors · doi:10.3390/chemosensors14090210
Govindhan, M., & Kavitha, G. (2026) · Next Materials · doi:10.1016/j.nxmate.2026.103603
Localized immunotherapy via dissolving microneedles for the prevention of breast cancer recurrence
Rathi, N., Kanaujiya, S., Mittal, K., Subhashchandra, G. K., Bhotiya, L., Pandey, P., Kumar, A., & Rajinikanth, P. S. (2026) · Drug Delivery and Translational Research · doi:10.1007/s13346-026-02217-3
Artificial intelligence in biomarker discovery for diseases: diagnostic and therapeutic prospects
Dinç, R., & Ardıç, N. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02946-4 · Cited by 1
Mumoli, N. (2026) · Italian Journal of Medicine · doi:10.4081/itjm.2026.2669
Reproducibility in Studies on Dental Restorative Materials: A Critical Review
Par, M., & Tarle, Z. (2026) · Materials · doi:10.3390/ma19194081
Algorithmic Limits and Reliability: The Legal Knot
Rotino, G. (2026) · Law for professionals · doi:10.1007/978-3-032-38537-6_4
Entwistle, T. R., Cowey, W. R., Stokoe, E., Stone, J. P., & Fildes, J. E. (2026) · PLoS ONE · doi:10.1371/journal.pone.0358773
“Second, despite the introduction of reporting guidelines including ARRIVE (2010, updated 2020) [44] and NIH principles for preclinical research (2014), methodological rigour has not substantively improved [45,46].”
Reproducibility in biomedical research
Zhong, J., D'Angelo, D., Lyu, C., Xu, I., Enns, P. K., Wang, F., & Kaushal, R. (2026) · Nature Medicine · doi:10.1038/s41591-026-04667-1
Basic aspects in biomedical research methodology
Khattab, M. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45595-7.00003-0
The validity and translatability of preclinical animal research
Pound, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26514-3.00016-3
Building confidence in new approach methodologies through reporting, validation, and benchmarking
Sunderic, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26514-3.00001-1
Sampling the survivors: A detachment-censoring hypothesis for under-reported ferroptosis
Ullah, W., Sulaiman, M., & Farooq, M. (2026) · Medical Hypotheses · doi:10.1016/j.mehy.2026.112186
Padulo, J. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12845-0
Reproducibility in Biomedical Science — From Repetition to Corroboration
Fineberg, H. V. (2026) · New England Journal of Medicine · doi:10.1056/nejmms2607020
Gannon, F. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-416049-1.00003-9
Dead Science Walking: Publication Bias and the AI Scientist Pipeline
Chauhan, K. (2026) · arXiv · doi:10.48550/arxiv.2606.04220
“In preclinical oncology, Begley & Ellis (2012) reported successful re-production of only 11 of 53 landmark studies.”
Metadata
- Authors
- Begley, C. G., & Ellis, L. M.
- Affiliations
- Amgen (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Ellis, Lee M.
- Venue
- Nature
- Published
- 2012-03-28
- Volume
- 483
- Issue
- 7391
- Pages
- 531-533
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1987777080
- Semantic Scholar
- 1a81d3d1e8a983e0551edf485f4ac1a8cdd7fea4
- Cited by
- 2,979
- References
- 5
- Citations by year
- 2026: 106 · 2025: 116 · 2024: 127 · 2023: 169 · 2022: 179 · 2021: 206 · 2020: 236 · 2019: 255 · 2018: 262 · 2017: 271 · 2016: 283 · 2015: 262 · 2014: 226 · 2013: 133 · 2012: 62
- FWCI
- 210.63
- Type
- journal article
- Language
- en
- Update notices
- correction (2012-05-02)
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- preclinical cancer research, research standards, publication practices, research incentives, translational research, clinical trials
- MeSH terms
- Animals, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Research Design, Reproducibility of Results, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.